EUVIMEDEUVIMED entdecken
Crossref

Analysis of Immune-Related Adverse Events of Pembrolizumab Using FAERS Database

Analyse immunbezogener unerwünschter Ereignisse von Pembrolizumab anhand der FAERS-Datenbank

Feilong Tan, Li Zhou, Guijiang Huang, Yanhua Li, Wenjie Yin, Hongying Xia

Oncology · 03.02.2025 · 103 (12) · 1147-1159

DOI: 10.1159/000543520 ↗

Auf einen Blick

In FAERS wurden 37.511 AE-Meldungen zu Pembrolizumab identifiziert. Die meisten Signale betrafen immunbezogene unerwünschte Ereignisse; Median bis zum Auftreten: 25 Tage.

Fragestellung

Welche unerwünschten Ereignisse sind in FAERS mit Pembrolizumab assoziiert?

Methode

FAERS-Analyse von Juli 2014 bis September 2023; Signalanalyse mit PRR; Auswertung nach SOC und PT gemäß MedDRA.

Ergebnisse

37.511 AE-Meldungen, 5.259 PTs, 22 SOCs. 931 positive Signale; die 10 stärksten Signale waren alle irAEs und IMEs. Median bis zum Auftreten 25 Tage (IQR 6–85); Weibull-Kurve mit frühem Versagensmuster.

Schlussfolgerung der Autor:innen

Es zeigten sich deutliche alters- und geschlechtsbezogene Unterschiede bei AE-Signalen unter Pembrolizumab, besonders bei irAEs. Auf mögliche irAEs zu Beginn der Behandlung sollte geachtet werden.

Kernaussagen

  • 37.511 AE-Meldungen zu Pembrolizumab in FAERS
  • 931 positive Signale; Top-10-Signale alle irAEs/IMEs
  • Median bis zum Auftreten: 25 Tage (IQR 6–85)

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, online erschienen am 03.02.2025. Verfasst von Feilong Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pembrolizumab is a PD-1 inhibitor that has been approved for the treatment of melanoma, non-small cell lung cancer, esophageal cancer and other malignant tumors. The safety profile of pembrolizumab across a broad patient population over an extended timeframe remains unverified. This study aims to investigate the adverse events (AEs) related to pembrolizumab and provide references for its safe and rational clinical use.

Methods

The study used FDA Adverse Event Reporting System (FAERS) data reported from July 2014 to September 2023, Risk estimation was conducted using the proportional reporting ratio (PRR). AEs were classified and analyzed according to the system organ class (SOC) and preferred term (PT) from the Medical Dictionary for Regulatory Activities (MedDRA).

Results

A total of 37,511 AE reports were identified, involving 5,259 PTs and 22 SOCs. Using the PRR method, 931 positive signals were detected. The top 10 risk signals were all immune-related AEs (irAEs) and important medical events (IMEs). The five PTs with the highest signal intensity were immune-mediated hypothyroidism, immune-mediated renal disorder, immune-mediated hepatic disorder, immune-mediated gastritis, and immune-mediated hyperthyroidism. The leading SOCs involved in AE reports were general disorders and administration site conditions, investigations, gastrointestinal disorders, respiratory, thoracic, and mediastinal disorders, and injury, poisoning, and procedural complications. The median time to onset of AE was 25 days (interquartile range [IQR] 6–85 days), with the Weibull distribution test indicating an early failure-type curve. Gender and age analysis revealed that women were more likely to develop hypertension, alopecia, headache, hypothyroidism, and palmar-plantar erythrodysesthesia syndrome, whereas men were more likely to develop interstitial lung disease, renal impairment, and death. Additionally, neutropenia was more prevalent in patients under 65 years of age, while interstitial lung disease and renal impairment were more common in patients aged 65 and above.

Conclusion

Significant age- and gender-related differences were observed in AE signals with pembrolizumab, particularly for irAEs. Clinical attention should be directed toward the potential occurrence of irAEs at the initial stages of drug administration, with appropriate measures implemented as necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsNeoplasmsAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedDatabases, FactualAgedAdultUnited StatesAged, 80 and overUnited States Food and Drug Administration

Stichwörter der Autor:innen

Data miningFDA Adverse Event Reporting SystemImmune-related adverse eventsPembrolizumabProportional reporting ratio

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.

Zitieren

APA

Tan, F., Zhou, L., Huang, G., Li, Y., Yin, W., & Xia, H. (2025). Analysis of Immune-Related Adverse Events of Pembrolizumab Using FAERS Database. Oncology, 103(12), 1147-1159. https://doi.org/10.1159/000543520

Vancouver

Tan F, Zhou L, Huang G, Li Y, Yin W, Xia H. Analysis of Immune-Related Adverse Events of Pembrolizumab Using FAERS Database. Oncology. 2025;103(12):1147-1159. doi:10.1159/000543520

BibTeX
@article{Tan2025,
  author = {Tan, Feilong and Zhou, Li and Huang, Guijiang and Li, Yanhua and Yin, Wenjie and Xia, Hongying},
  title = {Analysis of Immune-Related Adverse Events of Pembrolizumab Using FAERS Database},
  journal = {Oncology},
  year = {2025},
  volume = {103},
  number = {12},
  pages = {1147--1159},
  doi = {10.1159/000543520}
}
Kostenlos starten →